S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:GILD

Gilead Sciences - GILD Stock Forecast, Price & News

$85.67
-0.38 (-0.44%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$85.29
$86.03
50-Day Range
$81.39
$89.47
52-Week Range
$57.17
$89.74
Volume
7.23 million shs
Average Volume
6.88 million shs
Market Capitalization
$107.45 billion
P/E Ratio
23.47
Dividend Yield
3.38%
Price Target
$88.55

Gilead Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
3.4% Upside
$88.55 Price Target
Short Interest
Healthy
1.19% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.58mentions of Gilead Sciences in the last 14 days
Based on 60 Articles This Week
Insider Trading
Selling Shares
$535,736 Sold Last Quarter
Proj. Earnings Growth
7.01%
From $6.85 to $7.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.95 out of 5 stars

Medical Sector

23rd out of 1,026 stocks

Biological Products, Except Diagnostic Industry

4th out of 167 stocks

GILD stock logo

About Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

GILD Stock News Headlines

Is Biotech Immunocore About To Make A 25% Price Move? (GILD)
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Mergers and Acquisitions in 2023 Off To A Strong Start (GILD)
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
An All-In-One Guide for Trading Metals
So many want to add metals to their portfolio. Metals can be a great way to protect your money and hedge against market downturns. But first, you need to know how. Download our FREE Guide to Metals Futures today from RJO Futures to get the information that you need to know to trade futures in metals. pixel
Maxim Group Keeps Their Buy Rating on Gilead Sciences (GILD)
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $80.00
3 Secrets To Consistent Trading Success
Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. pixel
Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences (NASDAQ:GILD) PT Raised to $81.00
Gilead Sciences (NASDAQ:GILD) Releases FY23 Earnings Guidance
Gilead Sciences (NASDAQ:GILD) Updates FY 2023 Earnings Guidance
Gilead Sciences (NASDAQ:GILD) PT Raised to $91.00
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

GILD Company Calendar

Ex-Dividend for 12/29 Dividend
12/14/2022
Dividend Payable
12/29/2022
Last Earnings
2/02/2023
Today
2/08/2023
Ex-Dividend for 3/30 Dividend
3/14/2023
Dividend Payable
3/30/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GILD
CUSIP
37555810
Employees
14,400
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$88.55
High Stock Price Forecast
$112.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+3.4%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
17 Analysts

Profitability

Net Income
$4.59 billion
Pretax Margin
21.31%

Debt

Sales & Book Value

Annual Sales
$27.28 billion
Cash Flow
$7.18 per share
Book Value
$16.91 per share

Miscellaneous

Outstanding Shares
1,254,240,000
Free Float
1,252,237,000
Market Cap
$107.45 billion
Optionable
Optionable
Beta
0.39

Social Links


Key Executives

  • Daniel P. O'DayDaniel P. O'Day
    Chairman & Chief Executive Officer
  • Andrew D. DickinsonAndrew D. Dickinson
    Chief Financial Officer
  • Merdad V. ParseyMerdad V. Parsey
    Chief Medical Officer
  • Flavius Martin
    Executive Vice President-Research
  • Diane E. WilfongDiane E. Wilfong
    Chief Accounting Officer & Senior Vice President













GILD Stock - Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings
or view top-rated stocks.

What is Gilead Sciences' stock price forecast for 2023?

17 brokerages have issued 1-year price targets for Gilead Sciences' stock. Their GILD share price forecasts range from $70.00 to $112.00. On average, they anticipate the company's share price to reach $88.55 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts price targets for GILD
or view top-rated stocks among Wall Street analysts.

How have GILD shares performed in 2023?

Gilead Sciences' stock was trading at $85.85 at the beginning of the year. Since then, GILD stock has decreased by 0.2% and is now trading at $85.67.
View the best growth stocks for 2023 here
.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decrease in short interest in January. As of January 15th, there was short interest totaling 14,930,000 shares, a decrease of 8.0% from the December 31st total of 16,220,000 shares. Based on an average daily volume of 7,960,000 shares, the days-to-cover ratio is presently 1.9 days.
View Gilead Sciences' Short Interest
.

When is Gilead Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our GILD earnings forecast
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its earnings results on Thursday, February, 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.17. The biopharmaceutical company earned $7.39 billion during the quarter, compared to analyst estimates of $6.63 billion. Gilead Sciences had a net margin of 16.83% and a trailing twelve-month return on equity of 44.46%. Gilead Sciences's revenue was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.69 EPS.
Read the conference call transcript
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, February 2nd. Shareholders of record on Wednesday, March 15th will be given a dividend of $0.75 per share on Thursday, March 30th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date is Tuesday, March 14th. This is a positive change from the stock's previous quarterly dividend of $0.73.
Read our dividend analysis for GILD
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 3.38%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 80.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 39.84% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences updated its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided earnings per share (EPS) guidance of $6.60-$7.00 for the period, compared to the consensus earnings per share estimate of $6.73. The company issued revenue guidance of $26.00 billion-$26.50 billion, compared to the consensus revenue estimate of $25.76 billion.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Parnassus Investments LLC (0.96%), California Public Employees Retirement System (0.69%), LSV Asset Management (0.52%), Swiss National Bank (0.41%), Sumitomo Mitsui Trust Holdings Inc. (0.34%) and Robeco Institutional Asset Management B.V. (0.29%). Insiders that own company stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey and Richard James Whitley.
View institutional ownership trends
.

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $85.67.

How much money does Gilead Sciences make?

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $107.45 billion and generates $27.28 billion in revenue each year. The biopharmaceutical company earns $4.59 billion in net income (profit) each year or $3.65 on an earnings per share basis.

How many employees does Gilead Sciences have?

The company employs 14,400 workers across the globe.

Does Gilead Sciences have any subsidiaries?
The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More
How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.

This page (NASDAQ:GILD) was last updated on 2/9/2023 by MarketBeat.com Staff